Carrie Daniel

Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

INTRODUCTION: Evidence on the association between irritable bowel syndrome (IBS) and mortality is conflicting. In this study, we estimated the association between IBS and all-cause and cause-specific mortality in the NIH-AARP Diet and Health Study. METHODS: IBS diagnoses between 1994 and 2008 were identified from Medicare claims data, and mortality outcomes through 2019 were obtained through linkage to the National Death Index. Using multivariable Cox proportional hazards regression models, we estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause and cause-specific mortality within partitioned follow-up time categories (>2–5, >5–8, >8–11, >11–14, >14–17, and >17 years) with adjustment for confounders, including habitual diet and proxies for personal health advocacy/healthcare access. RESULTS: Of 132,697 individuals with available data, 5,030 (3.8%) had a prevalent IBS diagnosis. During the earliest follow-up interval (>2–5 years), the risk of all-cause mortality among individuals with IBS was 25% lower compared with those without IBS (HR = 0.75, 95% CI: 0.64–0.88), in the fully adjusted model. The inverse association attenuated over time such that during the >17-year follow-up interval, individuals with IBS had only an 8% lower risk of all-cause mortality (HR = 0.92, 95% CI: 0.87–0.98). Individuals diagnosed with IBS also had a lower risk of cancer and cardiovascular disease mortality, which attenuated over time. DISCUSSION: We found time-dependent inverse associations between IBS and all-cause, cancer and cardiovascular disease mortality. Although this association seemed to be strongly confounded by personal health advocacy/healthcare access during very short follow-up, further research is needed to explore the factors contributing to these associations observed after longer follow-up.

Year:

2026

Background/Objectives: Immune checkpoint blockade (ICB) therapies have significantly improved outcomes in metastatic melanoma. However, immune-related adverse events (irAEs) and persistent chronic toxicities (CTs) among this emerging survivor population likely influence different facets of quality of life. This study characterized CT, patient-reported outcomes (PROs), diet, physical activity and gut microbiome features in a cohort of long-term survivors with a history of ICB-treated metastatic melanoma. Methods: Forty-eight patients with a history of metastatic melanoma who initiated ICB treatment at least 3 years earlier and were not currently on treatment were prospectively enrolled from a melanoma survivorship clinic. Participants completed screening questionnaires for depression, anxiety, diet and physical activity. The gut microbiome was characterized via metagenomic sequencing in a subsample (n = 39). Patients’ clinicopathological characteristics and experience of irAEs (during treatment) and CT (persisting >6 months after completion of therapy) were extracted retrospectively from the medical record. Results: In the overall cohort, 60% were experiencing CT, while 16% and 20% reported clinically relevant levels of depression and anxiety symptoms, respectively. We observed significant differences in overall gut microbiome composition between survivors with and without CT (p = 0.02). Consumption of fruit and vegetables was inversely associated with anxiety (ρ = 0.3, p = 0.038). Added sugar consumption was correlated with the severity of experienced symptoms (ρ = 0.4, p = 0.003), with pronounced associations across the spectrum of symptoms, including pain, fatigue and shortness of breath (p < 0.05). Conclusions: These results suggest that CT is experienced by a substantial proportion of ICB-treated metastatic melanoma survivors. Patients experiencing CT also showed distinct microbiome features. However, additional research in prospective settings is needed to confirm these hypotheses.

Year:

2025

Purpose: To determine the association of grade group (GG) 1 core positivity with rates of adverse pathology in intermediate-risk prostate cancer, hypothesizing that inclusion of GG1 core positivity in National Comprehensive Cancer Network (NCCN)–based stratification is not associated with rates of adverse pathology at the time of surgery. We additionally explored use of targeted biopsy results from MRI-detected lesions in improving risk stratification. Methods: We included 307 fusion biopsy patients with intermediate risk disease who underwent radical prostatectomy. Modified intermediate-risk disease, as determined by biopsy, was defined using the same criteria as NCCN stratification, with the exception that GG1 positive cores were not counted as part of the core-positivity equation. We additionally evaluated a novel classification scheme based on MRI-visible presence of GG3 disease using data from targeted fusion biopsy. Results: Using current criteria, 144 patients (46.9%) had favorable risk disease, while 175 (57%) did with modified criteria, representing a change in 31 patients (19%). AUC for prediction of adverse pathology using traditional criteria was 0.552 and 0.551 using modified criteria ( P = .97). AUC for predicting adverse pathology when stratifying those men with GG3 disease and/or a total MRI-visible GG2 or GG3 tumor volume of 11.5 mm or higher as unfavorable had an AUC of 0.611 ( P = .048). Conclusions: Inclusion of GG1 core positivity in the determination of unfavorable disease stratification is not associated with rate of adverse pathology. Inclusion of MRI-visible tumor grade and volume data may improve risk stratification.

Year:

2025

Immune cell analysis by BMI and sex. A. Immunohistochemistry (IHC) analysis of the MDA cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis of the Gide cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor.

Year:

2025

Integrated gene set enrichment analysis of subgroups by body mass index BMI. This figure compares gene expression between overweight/obese (OW/OB) and normal (NL) BMI patients with metastatic melanoma across subgroups by sex, cohort, and tissue site. Supplementary Figure 2 presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients by subgroups. Red indicates upregulation in OW/OB verse NL.

Year:

2025

Integrated gene set enrichment analysis by body mass index (BMI) with correction for S phase. This figure presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients. Red indicates upregulation in OW/OB verse NL. The far left column is all patients, and then, an analysis controlling for sex, cohort, and tissue site is shown in the 3 columns to the right.

Year:

2025

Inverse Simpson alpha diversity scores of the fecal microbiome by BMI in patients with metastatic melanoma stratified by sex. Box plot represents the median bar with the box bounding the IQR and whiskers the most extreme points within 1.5 x IQR. The red dots represent OW/OB patients and the blue dots represent NL patients by BMI. This is a subgroup analysis of Figure 5C.

Year:

2025

Direct metabolite measurements from a subset of The Cancer Genome Atlas (TCGA) cohort. Comparison of additional tricarboxylic acid cycle metabolites measured by liquid chromatography/mass spectrometry between metastatic melanoma tumors from overweight/obese (OW/OB) patients by body mass index (BMI) verse normal (NL) BMI from The Cancer Genome Atlas (TCGA). Lines represent mean +/- SEM; each dot represents a single tumor.

Year:

2025

Immune cell analysis by BMI. A. Immunohistochemistry (IHC) analysis for CD8-, CD45RO-, FOXP3-, CD68-, GZMB-, PD-1-, LAG-3-, and CD3-positive cells in overweight/obese (OW/OB) verse normal (NL) tumors as defined by body mass index from the MD Anderson Cancer Center (MDA) cohort. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis for PD-L1-, CD45RO-, FOXP3-, EOMES-, GZMB-, PD-1-, TBET-, and TBET:FOXP3-positive cells in OW/OB verse NL tumors as defined by body mass index from the Gide cohort. Line represents median +/- interquartile range; each dot represents a single tumor.

Year:

2025

Supplementary Table 1: Baseline characteristics for patients included in the integrated gene set enrichment analysis (Figure 2-3) by cohort; Supplementary Table 6: The most frequent somatic alterations (alts) in patients with regionally metastatic melanoma by body mass index from The Cancer Genome Atlas cohort; Supplemental Table 7: Integrated gene set enrichment analysis for pathways associated with fatty acid metabolism by body mass index; Supplemental Table 8: Gene expression of selected genes of interest involved in fatty acid metabolism.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (33)

Georgina V. Long

University of Sydney

AUSTRALIA
View details

Lauren Haydu

Assistant Professor of Biostatistics

Mayo Clinic

UNITED STATES
View details

Michael A. Davies

-

UNITED STATES
View details

Chantale Bernatchez

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ralph J. DeBerardinis

University of Texas Southwestern Medical Center

UNITED STATES
View details

Jennifer L. McQuade

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jun Li

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Alexander M. Menzies

University of Sydney

AUSTRALIA
View details

Xiaotao Zhang

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Theodore S. Nowicki

University of California

UNITED STATES
View details

Greg M. Delgoffe

-

UNITED STATES
View details

Daniela Gutiérrez Torres

Staff Scientist

National Heart Lung and Blood Institute

UNITED STATES
View details

John Kirkwood

Distinguished Service Professor of Medicine

University of Pittsburgh

UNITED STATES
View details

Andrew Futreal

Chair and Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Vashisht Yennu Nanda

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

John Thompson

Clinical Professor

University of Sydney

AUSTRALIA
View details

Grant Fischer

Assistant Professor of Molecular Genetic Pathology (Tenure Track)

University of North Carolina at Chapel Hill

UNITED STATES
View details

Alexandra Ikeguchi

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Burton

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Aditya Mishra

University of Georgia

UNITED STATES
View details

Erikka Loftfield

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Christine Spencer

Parker Institute for Cancer Immunotherapy

UNITED STATES
View details

Dirk Schadendorf

University Hospital Essen

GERMANY
View details

Han Liang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

James Wilmott

Associate Professor

The University of Sydney Library

AUSTRALIA
View details

yana najjar

University of Pittsburgh

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christine Peterson

Associate Professor

Rice University

UNITED STATES
View details

Nadim Ajami

Executive Director

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Richard A. Scolyer

Faculty Member

University of Sydney

AUSTRALIA
View details

Nagireddy Putluri

Professor (Tenured)

Baylor College of Medicine

UNITED STATES
View details

Weiyi Peng

Director

University of Houston

UNITED STATES
View details